{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:16:56Z","timestamp":1763749016098,"version":"3.37.3"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease of 2019 (COVID-19), has caused havoc around the world. While several COVID-19 vaccines and drugs have been authorized for use, these antiviral drugs remain beyond the reach of most low- and middle-income countries. Rapid viral evolution is reducing the efficacy of vaccines and monoclonal antibodies and contributing to the deaths of some fully vaccinated persons. Others with normal immunity may have chosen not to be vaccinated and remain at risk if they contract the infection. Vaccines may not protect some immunodeficient patients from SARS-CoV-2, who are also at increased risk of chronic COVID-19 infection, a dangerous stalemate between the virus and a suboptimal immune response. Intra-host viral evolution could rapidly lead to the selection and dominance of vaccine and monoclonal antibody-resistant clades of SARS-CoV-2.<\/jats:p>\n               <jats:p>There is thus an urgent need to develop new treatments for COVID-19. The NZACE2-P\u0101tari project, comprising modified soluble angiotensin-converting enzyme 2 (ACE2) molecules, seeks to intercept and block SARS-CoV-2 infection of the respiratory mucosa. In vitro data presented here show that soluble wild-type ACE2 molecules retain the ability to effectively block the Spike (S) glycoprotein of SARS-CoV-2 variants including the ancestral Wuhan, delta (B.1.617.2) and omicron (B.1.1.529) strains. This therapeutic strategy may prove effective if implemented early during the nasal phase of the infection and may act synergistically with other antiviral drugs such as Paxlovid to further mitigate disease severity.<\/jats:p>","DOI":"10.1093\/cei\/uxad096","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T08:29:38Z","timestamp":1691742578000},"page":"289-295","source":"Crossref","is-referenced-by-count":4,"title":["Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19"],"prefix":"10.1093","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3011-8654","authenticated-orcid":false,"given":"Rohan","family":"Ameratunga","sequence":"first","affiliation":[{"name":"Department of Clinical immunology, Auckland Hospital , Auckland New Zealand"},{"name":"Department of Virology and Immunology, Auckland Hospital , Auckland , New Zealand"},{"name":"Department of Molecular Medicine and Pathology, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland , Auckland , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Mears","sequence":"additional","affiliation":[{"name":"Applied Translational Genetic Group, School of Biological Sciences, University of Auckland , Auckland , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Euphemia","family":"Leung","sequence":"additional","affiliation":[{"name":"Auckland Cancer Society Research Centre, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland , Auckland , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Snell","sequence":"additional","affiliation":[{"name":"Applied Translational Genetic Group, School of Biological Sciences, University of Auckland , Auckland , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"See-Tarn","family":"Woon","sequence":"additional","affiliation":[{"name":"Department of Virology and Immunology, Auckland Hospital , Auckland , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Kelton","sequence":"additional","affiliation":[{"name":"Te Huataki Waiora School of Health, University of Waikato , Hamilton , New Zealand"},{"name":"Te Aka M\u0101tuatua School of Science, University of Waikato , Hamilton , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Medlicott","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Otago , Dunedin , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Clinical immunology, Auckland Hospital , Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Abbott","sequence":"additional","affiliation":[{"name":"Department of Surgery, Auckland Hospital , Auckland , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Steele","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Wellington Hospital , Wellington , New Zealand"},{"name":"Department of Virology and Immunology, Auckland Hospital , Auckland , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Rolleston","sequence":"additional","affiliation":[{"name":"South Pacific Sera , Timaru , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Longhurst","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland , Auckland , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Lehnert","sequence":"additional","affiliation":[{"name":"Applied Translational Genetic Group, School of Biological Sciences, University of Auckland , Auckland , New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"2023121404032573600_CIT0001","first-page":"e8399","article-title":"Protective adaptive immunity against severe acute respiratory syndrome coronaviruses 2 (SARS-CoV-2) and implications for vaccines","volume":"12","author":"Manners","year":"2020","journal-title":"Cureus"},{"key":"2023121404032573600_CIT0002","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14760584.2022.2089120","article-title":"SARS-CoV-2 the ASIA virus (Autoimmune\/Autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy","volume":"21","author":"Ameratunga","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"2023121404032573600_CIT0003","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1016\/j.vaccine.2018.07.074","article-title":"Autoimmune diseases after hepatitis B immunization in adults: literature review and meta-analysis, with reference to \u2018Autoimmune\/Autoinflammatory Syndrome Induced by Adjuvants\u2019 (ASIA)","volume":"36","author":"Elwood","year":"2018","journal-title":"Vaccine"},{"key":"2023121404032573600_CIT0004","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jaip.2017.06.033","article-title":"Evidence refuting the existence of Autoimmune\/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)","volume":"5","author":"Ameratunga","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023121404032573600_CIT0005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2017.11.033","article-title":"Perspective: scientific and ethical concerns pertaining to animal models of Autoimmune\/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)","volume":"17","author":"Ameratunga","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2023121404032573600_CIT0006","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10875-021-01187-0","article-title":"First identified case of fatal fulminant necrotizing eosinophilic myocarditis following the initial dose of the Pfizer-BioNTech mRNA COVID-19 vaccine (BNT162b2, Comirnaty): an extremely rare idiosyncratic hypersensitivity reaction","volume":"42","author":"Ameratunga","year":"2022","journal-title":"J Clin Immunol"},{"key":"2023121404032573600_CIT0007","first-page":"792","volume-title":"COVID-19 vaccine breakthrough infections reported to CDC - United States","author":"CDC","year":"2021"},{"key":"2023121404032573600_CIT0008","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jaip.2022.06.011","article-title":"SARS-CoV-2 omicron: light at the end of the long pandemic tunnel or another false dawn for immunodeficient patients","volume":"10","author":"Ameratunga","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023121404032573600_CIT0009","doi-asserted-by":"crossref","first-page":"798389","DOI":"10.3389\/fimmu.2021.798389","article-title":"Common variable immunodeficiency disorders as a model for assessing COVID-19 vaccine responses in immunocompromised patients","volume":"12","author":"Ameratunga","year":"2021","journal-title":"Front Immunol"},{"key":"2023121404032573600_CIT0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaip.2022.10.002","article-title":"Selective IgA deficiency may be an underrecognized risk factor for severe COVID-19","volume":"11","author":"Ameratunga","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023121404032573600_CIT0011","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1016\/j.jaip.2021.06.019","article-title":"Common variable immunodeficiency disorders, t-cell responses to SARS-CoV-2 vaccines, and the risk of chronic COVID-19","volume":"9","author":"Ameratunga","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023121404032573600_CIT0012","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/1744666X.2021.1905525","article-title":"Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection","volume":"17","author":"Ameratunga","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2023121404032573600_CIT0013","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/1744666X.2021.1982386","article-title":"Response to letter to the editor: the clinical utility of diagnostic T cell assays for COVID-19","volume":"17","author":"Ameratunga","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2023121404032573600_CIT0014","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jcp-2022-208305","article-title":"Critical role of diagnostic SARS-CoV-2 T cell assays for immunodeficient patients","volume":"75","author":"Ameratunga","year":"2022","journal-title":"J Clin Pathol"},{"key":"2023121404032573600_CIT0015","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s10875-020-00904-5","article-title":"Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy","volume":"41","author":"London","year":"2021","journal-title":"J Clin Immunol"},{"key":"2023121404032573600_CIT0016","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/ccr3.3786","article-title":"COVID-19: prolonged viral shedding in an HIV patient with literature review of risk factors for prolonged viral shedding and its implications for isolation strategies","volume":"9","author":"Yousaf","year":"2021","journal-title":"Clin Case Rep"},{"key":"2023121404032573600_CIT0017","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/d41586-023-00347-z","article-title":"COVID drug drives viral mutations - and now some want to halt its use","volume":"614","author":"Callaway","year":"2023","journal-title":"Nature"},{"key":"2023121404032573600_CIT0018","first-page":"112","article-title":"Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection","volume":"133","author":"Ameratunga","year":"2020","journal-title":"N Z Med J"},{"key":"2023121404032573600_CIT0019","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2023121404032573600_CIT0020","first-page":"28046","article-title":"Engineered ACE2 receptor traps potently neutralize SARS-CoV-2","volume-title":"Proc Natl Acad Sci U S A","author":"Glasgow","year":"2020"},{"key":"2023121404032573600_CIT0021","first-page":"553","article-title":"Perspective: the nose and the stomach play a critical role in the NZACE2-P\u0101tari* (modified ACE2) drug treatment project of SARS-CoV-2 infection","volume-title":"Expert Rev Clin Immunol","author":"Ameratunga","year":"2021"},{"key":"2023121404032573600_CIT0022","doi-asserted-by":"crossref","first-page":"2057832","DOI":"10.1080\/19420862.2022.2057832","article-title":"David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors","volume":"14","author":"Alfaleh","year":"2022","journal-title":"MAbs"},{"key":"2023121404032573600_CIT0023","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41589-021-00965-6","article-title":"Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants","volume":"18","author":"Zhang","year":"2022","journal-title":"Nat Chem Biol"},{"key":"2023121404032573600_CIT0024","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1021\/acs.jcim.1c00783","article-title":"Computationally designed ACE2 decoy receptor binds SARS-CoV-2 Spike (S) protein with tight nanomolar affinity","volume":"61","author":"Havranek","year":"2021","journal-title":"J Chem Inf Model"},{"key":"2023121404032573600_CIT0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41421-021-00302-0","article-title":"Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo","volume":"7","author":"Zhang","year":"2021","journal-title":"Cell Discov"},{"key":"2023121404032573600_CIT0026","doi-asserted-by":"crossref","first-page":"eabf1738","DOI":"10.1126\/sciadv.abf1738","article-title":"An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants","volume":"7","author":"Chan","year":"2021","journal-title":"Sci Adv"},{"key":"2023121404032573600_CIT0027","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.tips.2022.06.011","article-title":"Engineering ACE2 decoy receptors to combat viral escapability","volume":"43","author":"Arimori","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"2023121404032573600_CIT0028","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/1744666X.2021.1912596","article-title":"Perspective: the nose and the stomach play a critical role in the NZACE2-Patari* (modified ACE2) drug treatment project of SARS-CoV-2 infection","volume":"17","author":"Ameratunga","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2023121404032573600_CIT0029","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"2023121404032573600_CIT0030","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2023121404032573600_CIT0031","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study","volume":"2","author":"Chia","year":"2021","journal-title":"Lancet Microbe"},{"key":"2023121404032573600_CIT0032","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2023121404032573600_CIT0033","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"2023121404032573600_CIT0034","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/bmj.p264","article-title":"Covid-19: FDA removes US authorisation for antibody drug Evusheld","volume":"380","author":"Iacobucci","year":"2023","journal-title":"BMJ"},{"key":"2023121404032573600_CIT0035","doi-asserted-by":"crossref","first-page":"e15230","DOI":"10.15252\/emmm.202115230","article-title":"Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants","volume":"14","author":"Monteil","year":"2022","journal-title":"EMBO Mol Med"},{"key":"2023121404032573600_CIT0036","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.actbio.2022.09.048","article-title":"An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension","volume":"153","author":"Fuchs","year":"2022","journal-title":"Acta Biomater"},{"key":"2023121404032573600_CIT0037","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.14309\/ajg.0000000000000798","article-title":"Increased risk of COVID-19 among users of proton pump inhibitors","volume":"115","author":"Almario","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2023121404032573600_CIT0038","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/gutjnl-2020-322248","article-title":"Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching","volume":"70","author":"Lee","year":"2021","journal-title":"Gut"},{"key":"2023121404032573600_CIT0039","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jhin.2020.07.009","article-title":"Factors affecting stability and infectivity of SARS-CoV-2","volume":"106","author":"Chan","year":"2020","journal-title":"J Hosp Infect"},{"key":"2023121404032573600_CIT0040","doi-asserted-by":"crossref","first-page":"e2201294","DOI":"10.1002\/advs.202201294","article-title":"Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection in vitro and in vivo","volume":"9","author":"Kayabolen","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"2023121404032573600_CIT0041","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/22221751.2022.2079426","article-title":"ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"2023121404032573600_CIT0042","doi-asserted-by":"crossref","first-page":"10617","DOI":"10.1038\/s41598-021-89957-z","article-title":"A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection","volume":"11","author":"Miller","year":"2021","journal-title":"Sci Rep"},{"key":"2023121404032573600_CIT0043","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.cmi.2020.07.029","article-title":"Personal protective equipment protecting healthcare workers in the Chinese epicentre of COVID-19","volume":"26","author":"Zhao","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023121404032573600_CIT0044","doi-asserted-by":"crossref","first-page":"m4763","DOI":"10.1136\/bmj.m4763","article-title":"Lightening the viral load to lessen COVID-19 severity","volume":"371","author":"Burgess","year":"2020","journal-title":"BMJ"},{"key":"2023121404032573600_CIT0045","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/v13020304","article-title":"Relationships between viral load and the clinical course of COVID-19","volume":"13","author":"Tsukagoshi","year":"2021","journal-title":"Viruses"},{"key":"2023121404032573600_CIT0046","first-page":"jiad135","article-title":"De novo human angiotensin-converting enzyme 2 decoy NL-CVX1 protects mice from severe disease after severe acute respiratory syndrome coronavirus 2 infection","volume":"5","author":"Rebelo","year":"2023","journal-title":"J Infect Dis"},{"key":"2023121404032573600_CIT0047","first-page":"01100","article-title":"Broadly effective ACE2 decoy proteins protect mice from lethal SARS-CoV-2 infection","volume":"3","author":"Lu","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2023121404032573600_CIT0048","doi-asserted-by":"crossref","first-page":"228","DOI":"10.7883\/yoken.JJID.2021.281","article-title":"Relationship between selective IgA deficiency and COVID-19 prognosis","volume":"75","author":"\u00c7\u00f6lkesen","year":"2022","journal-title":"Jpn J Infect Dis"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxad096\/53851369\/uxad096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/214\/3\/289\/54429042\/uxad096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/214\/3\/289\/54429042\/uxad096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T04:07:53Z","timestamp":1702526873000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/214\/3\/289\/7241066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,8,11]]},"published-print":{"date-parts":[[2023,12,13]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxad096","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"type":"print","value":"0009-9104"},{"type":"electronic","value":"1365-2249"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,8,11]]}}}